SELECT: Weight drug, heart benefit | Hormone Insight Podcast cover image

SELECT: Weight drug, heart benefit | Hormone Insight Podcast

SELECT: Weight drug, heart benefit | Hormone Insight Podcast

Listen for free

View show details

This Season's Biggest Deal | 0.99 €/mo for 3 months + 15 € Audible bonus

6.99 €/month thereafter - terms apply. Cancel monthly.
Summary

Does weekly subcutaneous semaglutide 2.4 milligrams reduce cardiovascular events in patients with obesity without diabetes?


In patients with established cardiovascular disease and overweight or obesity but without diabetes, once-weekly semaglutide 2.4 mg reduced major adverse cardiovascular events more than placebo.


Randomized trial · NEJM 2023

Reference: Lincoff AM, Brown-Frandsen K, Colhoun HM. N Engl J Med. 2023; PMID:37952131.


Chapters

0:00 Intro

0:38 The trial

3:05 My take

3:42 Outro


Read the structured trial summary at https://hormoneinsight.com/


AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.


Explore Hormone Insight:

Website: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

adbl_web_anon_alc_button_suppression_t1
No reviews yet